Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Gilteritinib

EU orphan designation number: EU/3/17/1961   
Active ingredient: Gilteritinib
Indication: Treatment of acute myeloid leukaemia
Sponsor: Astellas Pharma Europe B.V.
Sylviusweg 62, 2333 BE Leiden, Nederland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
19/01/2018 Orphan designation EMA/OD/175/17 (2018)382 of 17/01/2018